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Summary The inhibitor of cyclin-dependent kinases WAF1/p21 has been shown to mediate cell cycle arrest by p53 and other factors. We
have studied its expression in urothelial carcinoma. Immunohistochemistry of paraffin-embedded tissues revealed no detectable p21 protein
in normal mucosa, whereas 8 of 17 (47%) carcinomata in situ, 41 of 62 (66%) pTa, 14 of 30 (47%) pTl and 5 of 15 (33%) muscle-invasive
tumours stained positive, usually with a heterogeneous pattern. Expression of p21 was associated with low grade tumours. In contrast, the
frequency of p53 accumulation increased with grade and stage as did the frequency of staining for the proliferation marker Ki67. The level of
WAF1 mRNA was determined relative to P-actin mRNA by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) in 15
freshly frozen invasive tumours. In eight samples obtained from normal bladder mucosa, the values ranged from 0.93 to 2.19 arbitrary units
(AU) (mean 1.54 ± 0.37 AU), but varied widely from non-detectable to 16.21 AU (mean 3.02 ± 4.44 AU) in the tumour specimens. In accord
with the immunohistochemical findings, WAF1 mRNA expression was elevated over the range found in normal mucosa in 5 of 15 advanced
tumours. In addition, RNA analysis revealed a decrease in expression in six tumours. No mutations were observed in the WAF1/p21 gene in
these tumours, but two were heterozygous forthe codon 31 polymorphism. These data indicate that p21 isfrequently expressed in superficial,
well differentiated urothelial carcinomas, but less often in muscle-invasive urothelial carcinomas, irrespective of their p53 status. The
expression of p21 and its prevalence in low-stage tumours may reflect residual growth-regulatory influences potentially impeding but not
necessarily inhibiting tumour development.
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Mutations and deregulation ofgenes involved in cell cycle control
appear to play a central role in the development ofurothelial carci-
noma. Genes involved in cell cycle control and affected in urothe-
lial carcinoma comprise MTSJ/p16 and MTS2/p15 encoding
inhibitors of cyclin-dependent kinases (CDKs) (Orlow et al,
1995), cyclin Dl (Bringuier et al, 1994), RB (Xu et al, 1993) and
MYC (Lipponen, 1995; Schmitz-Drager et al, 1996). In addition,
depending on stage and grade, a considerable fraction ofurothelial
carcinomas display accumulation of p53 protein usually due to
point mutations in the gene (Wright et al, 1991; Cordon-Cardo et
al, 1994; Esrig et al, 1994; Schmitz-Drageret al, 1994; Williamson
et al, 1994; Uchida et al, 1995; Vet et al, 1995).
The wild-type p53 protein is capable of arresting the cell cycle
in response to DNA damage by inducing a further CDK inhibitor
WAF1/p21 (El-Deiry et al, 1993). Increased expression of p21 is
also observed in some cell types undergoing terminal differentia-
tion or senescence and may contribute to these processes (Halevy
et al, 1995; McLeod et al, 1995; Missero et al, 1995; Parker et al,
1995). Although over-expression of p21 has been shown to
suppress tumour formation (Chen et al, 1995; Yang et al, 1995)
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several animal tumour models (El-Deiry et al, 1995; Missero et al,
1996), surveys on a variety of human tumours have revealed the
WAFI/p21 gene to be infrequently mutated (Shiohara et al, 1994;
Gao et al, 1995; Watanabe et al, 1995). Instead, expression ofp21
has been found in human tumours of different origin (Barboule et
al, 1995; Ozcelik et al, 1995; Marchetti et al, 1996).
In urothelial carcinoma, WAFI/p21 mRNA has been shown to
be expressed by reverse transcriptase polymerase chain reactions
(RT-PCR). Among 28 tumours, four contained mutations in the
gene (Malkowicz et al, 1996). Here, we report on the expression of
p21 in urothelial carcinoma using immunohistochemistry to detect
expression of the protein through several stages of tumour devel-
opment. In addition, p53 protein accumulation was compared in
the same tumour specimens to determine whether induction ofp21
might be mediated by p53 and the MIB1 antibody detecting the
Ki67 antigene was used to investigate the proliferation status.
Quantitative RT-PCR was used to measure WAFI mRNA levels in
advanced tumours, and these tumours were screened for mutations
in the WAF] gene.
MATERIALS AND METHODS
Patients and specimens
For immunohistochemistry, archival paraffin-embedded tumour
specimens were derived from patients treated for primary or
recurrent bladder tumours at the Department of Urology of the
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Heinrich-Heine University between 1985 and 1992. The speci-
mens comprised 17 carcinomata in situ (pTIS), 62 pTa tumours,
30 pTl tumours, and 15 muscle-infiltrating (pT2 or pT3) tumours.
Fifteen pTa and one pTl lesion were classified as GI, 39 pTa, 13
pT1 and 9 muscle-invasive tumours were classified as G2, and
seven pTa, 16 pTl and six muscle-invasive tumours were
classified as G3. All histological sections were reviewed by a
pathologist and material adequate for immunohistochemistry was
selected. Histological typing and grading was performed
according to the WHO classification (Mostofi, 1973). The tumour
stage was determined according to the UICC recommendations
(Hermanek and Sobin, 1992). Non-invasive, non-papillary lesions
characterized by marked hyperchromasive nuclear and cellular
pleomorphism were classified as carcinoma in situ (CIS) (Mostofi,
1973; Koss, 1975).
For RNA analysis, tumour tissue and normal mucosa - when
available - were dissected from 15 further, distinct patients under-
going radical cystectomy for bladder cancer, shock-frozen and
kept at -80°C. Histologically, all tumour samples represented
urothelial carcinoma, except for one adenocarcinoma (tumour no.
36). Two tumours (nos 35 and 41) displayed pronounced squa-
mous epithelial metaplasia.
Immunohistochemistry
Paraffin sections were analysed immunohistochemically for p21
expression, p53 accumulation, and Ki67 staining using a standard
avidin-biotin technique. Briefly, 5- to 10-,um sections were
deparaffinized using xylene and ethanol for 15 and 10 min respec-
tively. Endogenous peroxidases were blocked by application of
1% hydrogen peroxide in methanol for 20 min. After rehydration,
sections were pretreated with 0.5% Triton X-100 in phosphate-
buffered saline (PBS) and unspecific reactions were blocked with
20% normal horse serum in 1% bovine serum albumin in PBS
(PBSA). For detection of p21, the antibody WAF-l (Ab-1, Clone
EAIO, Oncogene research) was applied at a 1:50 dilution in PBSA
overnight at room temperature. For detection of p53 the antibody
DO-1 was applied at a 1:100 dilution in PBSA and incubated
overnight at 37°C. The monoclonal antibody DO-1 (Ab-6;
Dianova, Hamburg, Germany) recognizes a denaturation-resistant
epitope on wild-type and mutant human p53 protein located
between amino acids 37 and 45. For detection ofthe Ki67 antigen,
the monoclonal antibody MIB1 (Dianova) was applied at a 1:50
dilution. To achieve optimal detection of this antigen, specimens
were pretreated by boiling in 10 mm sodium citrate, pH 6, four
times for 5 min each. For all antibodies, after several washes in
PBSA, binding was visualized using biotinylated horse anti-
mouse antibodies and avidin-biotin-peroxidase complex (Vector,
Burlingame, CA, USA), both diluted 1:100 in PBSA with
diaminobenzidine as the chromogen. Counterstaining was
performed with Mayer's haemalum (Merck, Darmstadt,
Germany). For all proteins, only nuclear staining was considered
positive. For p21, a lesion was counted as positive if nuclear
staining of more than 5% of cells was observed in at least one
region ofthe tumour. For p53, nuclear staining ofmore than 5% of
cells in several areas of the tumour was considered positive.
Staining for Ki67 was evaluated by counting of cells in several
distinct areas of the specimen. Controls for specificity of staining
were performed by omitting the primary antibodies and were
carried along in each experiment.
RNA extraction and quantitative RT-PCR
Total tissue RNA was extracted by guanidium chloride-acid
phenol-chloroform, followed by chloroform re-extraction and
isopropanol precipitation. Purified RNA was dissolved in RNAase-
free water and quantitated by spectrophotometry. Reverse tran-
scription was performed using a Reverse Transcription Kit
(Promega, Heidelberg, Germany) with oligo-dT priming under
standard conditions suggested by the supplier. Aliquots were used
for PCR amplification using 20 pmol each of primers Waf-S
(5'-GCGACTGTGATGCGCTAATG-3') and Waf-AS (5'-AGAA-
GATCAGCCGGCGT'TTG-3') for WAFI (corresponding to bases
170-189 and 553-534, respectively, of WAF-1 cDNA) and
Aktin-S (5'-TGACGGGGTCACCCACACTGTGCCCATCTA-3')
and Aktin-AS (5'-CTAGAAGCATFlTGCGGTGGACGATGGA-
GGG-3') for P-actin (corresponding to bases 1038-1067 and
1905-1876, respectively, ofP-actin cDNA) in 20 mM Tris-HCl (pH
8.3), 1.5 mm magnesium chloride, 50 mm potassium chloride, 1
mnim dithiothreitol with 100gM of each deoxynucleotide triphos-
phate, 5.25 jM digoxigenin-dUTP and 0.5 U Taq polymerase in a
total volume of 50 ,ul. An initial cycle was performed for 5 min at
96°C, 5 min at 60°C and 1 min at 72°C followed by a number of
cycles each for 30 s at 96°C, 45 s at 60°C and 1 min at 72°C. After
the final cycle, PCR products were separated on a 1.6% agarose
gel, blotted to a Hybond-N nylon membrane (Amersham,
Braunschweig, Germany) and detected using anti-digoxigenin anti-
body coupled to peroxidase and a luminescence reaction. Films
were exposed for various times and appropriately exposed lumino-
graphs wereusedforquantitative evaluation by videodensitometry.
Expression ofP-actin mRNA was used to standardize the results.
To ensure quantitative amplification and to define the linear range
of the reaction, a standard curve was constructed using RNA from
the bladder carcinoma cell lines 639V, HT1376 and one tumour
from which the amplification factor was estimated as 1.68 percycle
for both messages. For each tumour and normal RNA, at least one
initial PCR reaction was performed using 25 cycles for WAF1 and
21 cycles for1-actin in the same reaction mix to ensure that WAF1
as well as 1-actin signals were within the linear range of the
reaction. Cycle numbers were adjusted accordingly for the few
samples yielding signals either too low or outside the linear range
ofamplification.
DNA extraction and mutation analysis
DNA was extracted from powdered frozen tissue using a commer-
cial affinity chromatography method (Qiagen, Hilden, Germany).
Using three sets of primer pairs the entire coding region of the
WAFI/p21 gene was amplified, as described by Shiohara et al
(1994). Aliquots of the amplification products were checked on
agarose gels and denatured for single-strand conformation poly-
morphism analysis by heating to 94°C for 10 min and shock
cooling. Samples were mixed with loading buffer and rapidly
loaded onto a 10% polyacrylamide gel in ice-cold
tris/borate/EDTA buffer. Two runs were performed for each
sample, at 4°C and at room temperature. After a 15 h run at 150 V,
bands were detected by silver staining. PCR products showing
bands deviating from those obtained with control lymphocytes
DNA and several with non-deviating bands were sequenced by
cycle sequencing using the same primers as for amplification
with fluorescence labelling and an automatic DNA sequencer
(Pharmacia, Freiburg, Germany).
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Table 1 Expression of p21 and accumulation of p53 in urothelial tumours at
different stages
Stage p21 staining p53 accumulation Total
Cis 8 (47%) 4 (24%) 17
pTa 41 (66%) 17 (27%) 62
pTl 14 (47%)a 9 (30%) 30
2pT2 5 (33%)a 7 (50%) 15b
Total 68 (55%) 37 (30%) 124b
aSignificantly different from pTa (P < 0.05). bOne tumour could not be
evaluated for P53 accumulation.
RESULTS
The p21 protein was not detectable by immunohistochemistry in
five specimens of normal urothelial epithelium, but was seen in
numerous specimens of urothelial carcinoma (Table 1). In some
tumours most nuclei stained positive for p21 (Figure 1A), whereas
the protein was nondetectable in others (Figure 1B). Very
frequently, p21 expression was heterogenous within one specimen
with staining intensity of individual nuclei ranging from unde-
tectable to very strong (Figure IC). Moreover, in a few tumours,
p21 staining involved almost all nuclei in certain areas of the
tumour, but few or none in others. Some lesions displayed weaker
staining in a small proportion of nuclei, whereas the majority was
negative (Figure ID). p21 staining was also detected in the nuclei
of some inflammatory cells.
Among 124 bladder tumour specimens, expression of p21 was
detected most frequently in pTa tumours (41 of 62 specimens,
66%). Positive staining for P21 was less frequently observed in
carcinomata in situ (8 of 17 specimens, 47%), in pTl tumours (14
of 30 specimens, 47%), and in muscle-invasive tumours (5 of 15,
33%). Statistical analysis by Fisher's exact test revealed the differ-
ences between pTa and pT1 lesions as well as between pTa and
muscle-invasive tumours to be significant (Table 1). The associa-
tion of p21 expression with low stage tumours was even more
pronounced if only strong staining for p21 (defined as > 20% of
nuclei positive) was considered (cf. Figure 1A and C vs D).
Strong staining was observed in 29% of carcinomata in situ, in
40% of pTa tumours, 23% of pTl tumours and 7% of muscle-
invasive tumours respectively.
The relationship between p21 staining and tumour grade is
summarized in Table 2. Sixty-nine per cent and 62% ofGI and G2
tumours, respectively, stained positive for p21 compared with 28%
of the G3 tumours. The difference between either G1 or G2
tumours and G3 tumours was highly significant.
Parallel sections of the same specimens were investigated for
accumulation of p53 (Tables 1 and 2). In accord with previously
published data (Schmitz-Drager et al, 1994; 1996), p53 accumula-
tion was most frequently observed in muscle-invasive tumours
(Table 1) and increased with tumour grade (Table 2). Overall, 30%
A B
D
Figure 1 Immunohistochemical detection of p21 protein in urothelial tumours. (A) Strong nuclear staining for p21 in a pTaGl tumour. (B) Lack of p21 staining
in a pTaG2 tumour. (C) Strong, heterogenous staining for P21 in a pTaG2 tumour. (D) Weak positive staining for p21 in a pTl G3 tumour
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Table 2 Expression of P21 and accumulation of P53 in urothelial tumours of
different gradesa
Grade p21 staining p53 accumulation Total
Gl 11 (69%) 1 (6%) 16
G2 38 (62%) 18 (30%)b 61
G3 8 (28%)- 14 (48%)c 29
Total 57 (54%) 33 (31%) 106
aGrading was not performed on carcinomata in situ. bSignificantly
different from G1 and G3 (P < 0.01). cSignificantly different from GI and
G2 (P< 0.01).




p21 staining + 23 44 67
- 15 41 56
Total 38 89 123
of the specimens displayed accumulation of p53. Among these,
61% (23 out of 38) stained positive for p21 compared with 52%
(44 out of 85) of the specimens without p53 accumulation (Table
3). Conversely, 34% (23 out of 67) of lesions with p21 staining
exhibited p53 accumulation compared with 27% (15 out of56) of
lesions without. Across all tumour stages, these data indicate a
significant correlation neither between p53 accumulation and lack
of p21 staining nor between p21 accumulation and lack of p53
staining. Notably, all four carcinomata in situ with p53 accumula-
tion also displayed positive staining for p21. Conversely, within
the group of muscle-invasive tumours none of the seven tumours
with p53 accumulation stained positive forp21.
To investigate the relation between tumour proliferation and
p21 expression, 107 specimens were additionally stained using the
MIB1 antibody directed against the proliferation marker Ki67
(Table 4a,b). As expected (Kruiger & Muller, 1995), staining for
MIB1 increased significantly with either stage or grade, as
analysed using X2 statistics. Accordingly, MIB1 staining tended
to show a pattern inverse to that seen with the antibody directed
against p21 (Table 4c). However, this trend was not statistically
significant.
The expression of WAF] mRNA was studied by quantitative
RT-PCR in 15 urothelial carcinoma samples and eight samples of
histologically normal bladder mucosa obtained from patients
undergoing radical cystectomy (Table 5). The samples from
normal mucosa expressed WAF] mRNA with little variation. In
arbitrary units (AU), expression ranged from 0.93 to 2.19 with a
mean of 1.54 and a standard deviation of 0.37. In contrast,
expression in tumour samples varied over a wide range from
undetectable to 16.21 AU (Table 5). The mean expression was
3.02 ± 4.44 AU, corresponding to 2.00 ± 2.88-fold that of normal
mucosa. Five out of the fifteen tumours displayed mRNA levels
surpassing the range of normal mucosa. In contrast, six tumours
had values below the normal level (Figure 2).
The fourteen tumours showing expression of WAFI mRNA
were analysed for the presence of mutation in the coding region.
DNA was available from 12 tumours. The entire p21 coding
Table 4 MIBl staining in urothelial tumours
a MIBl staining in relation to tumour stage
Per cent of nuclei staining Cis pTa pTl > T2 Overall
<5% 5 14 0 0 19
5-10% 1 18 5 1 25
10-25% 4 19 11 6 40
> 25% 1 8 10 4 23
Total 11 59 26 11 107
b MIBl staining in relation to tumour gradea
Per cent of nuclei staining Gl G2 G3 Overall
<5% 4 7 3 14
5-10% 7 14 3 24
10-25% 5 20 11 36
> 25% 0 13 9 22
Total 16 54 26 96
aNo grading was performed on carcinomata in situ
c Comparison of MIBl and p21 staining
Tumour stage Positive staining Weak staining Overall (100%)
for P21a (%) for MlBlb (%)
Cis 5 (45) 6 (54) 11
pTa 40 (68) 32 (54) 59
pTl 14 (54) 5 (19) 26
> pT2 4 (36) 1 (9) 11
Total 63 (59) 44 (41) 107
aMore than 5% of nuclei positive. bLess than 10% of nuclei positive.
region was amplifiedusing twopairs ofprimers forexon 2 and one
pair for the 5'-part of exon 3. All fragments were subjected to
single-strand conformation analysis. Two tumours (nos 33 and 35
in Table 5) yielded identical aberrant bands with primers for the
upstream part of exon 2. Upon sequencing, both samples turned
out to be heterozygous forthe previously describedpolymorphism
at codon 31, in which one allele reads AGC encoding serine and
the other reads AGA encoding arginine. This polymorphism may
occur in up to 15% ofthe human population (Shiohara et al, 1994).
True mutations were not detected in any of the tumours. To
analyse the two tumours from which only RNA was available, the
product from the RT-PCR reaction was excised from an agarose
gel and sequenced. No mutations were found in the approximately
250 bp that could be unambigously read.
DISCUSSION
In spite ofits obvious association with terminal differentiation and
senescence (Halevy et al, 1995; McLeod et al, 1995; Missero et al,
1995; Parker et al, 1995) the WAFI gene product p21 has been
found to be expressed in several human tumours, such as breast
(Ozcelik et al, 1995) and ovarian carcinoma (Barboule et al, 1995)
and non-small cell lung cancer (Marchetti et al, 1996). In line with
these findings, the data presented here demonstrate frequent
expression of p21 in urothelial cancer. A comparison of p21
expression patterns in the different tumour species reveals several
similarities.
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Table 5 p21 mRNA expression in bladder cancer
Number Gender Age Stage Grade P21 RNA Ratio
tumour (AU) Tumour-mucosa
1 F 77 pT3b G3 0.42 0.27
3 M 60 pT3b G3 0 0
4 M 60 pT3b G3 0.99 0.64
8 M 61 pT3b G3 1.61 1.54
14 M 54 pTa + Cis G2 1.11 0.72
17 F 72 pT4a G3 0.22 0.14
19 M 60 pT3b G3 9.24 6.00
21 M 74 pTa G2 1.76 1.14
32 F 76 pT3b G3-4 0.35 0.23
33 M 63 pT4a G3 0.79 0.51
35 M 73 pT3b G2 16.21 10.53
36 M 58 pT2 G3 2.8 1.82
37 M 66 pT3b G3 0.28 0.18
39 M 66 pT3b G3 5.86 3.81
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Figure 2 WAF-1 mRNA expression in urothelial tumours. Expression of WAF-1 mRNA relative to 3-actin mRNA in 15 urothelial carcinomas as determined by
RT-PCR. The dotted lines indicate the range of expression in normal mucosa
First, a pronouniced heterogeneity of p2 1 expression, often
within onie tulmoui as well as between different tum)ours of iden-
tical stage anid grade. was observed not only in urothelial carci-
nomiia but also in ovarian and breast carcinomiias. The reasons for
this heterogeneity are not obvious. In breast carciniomiia, intertu-
moral heterogeneity appears to be well explained by the presence
or absenice of p53 accumulation, which is not the case in the other
tumours. Intratulmor-al heterogeneity may be due to a dependence
of p21 expression on the cell cycle stage (Li et al, 1994).
Second, in non-smiiall-cell lung carcinomas p2 ImRNA and
protein expression was associated with well-differentiated
tumours. Likewise, in urothelial carcinomiia WAFI expression was
most frequently observed in tumours with low grading. The
highest frequency of p2 1 expression was seen in the species with
the most favourable prognosis. i.e. low-grade papillary tumours. In
comparison, a lower frequency was seen in carcinoma in situ that
is known to progress more often. As p2 1 has been shown to
becomiie induced by growth-regulating peptides (Datto et al, 1995:
Osawa et al, 1995: Jakus and Yeudall, 1996), its expression in
lower grade and stage tumours may reflect residual growth control
mechanismiis active in these species. The tendency of p21 protein
expression to be associated with low staining indices for the prolif-
eration marker Ki67 (Table 4c) - albeit not statistically significant
- is in line with this notion.
Third, with the possible exception of breast canicer, p2 1 expres-
sion did not correlate well with the p53 status in other tumours
indicating that the relationship between p53 and p2 1 expression is
complex. Wild-type p53 has been shown to induce p21 in several
cell types after its activation as a consequence of damage to DNA
(El-Deiry et al, 1993; McLeod et al, 1995). Induction of p21
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expression can also be affected in a p53-independent fashion. For
instance, approximately five- to tenfold increases of WAF] mRNA
expression accompany terminal differentiation and cellular senes-
cence (Halevy et al, 1995; McLeod et al, 1995; Missero et al,
1995; Parker et al, 1995). It is not thought that p53 is involved in
either of these inductions, but it may affect the basal level of
WAFI expression (McLeod et al, 1995). In urothelial carcinoma
accumulation of p53 protein increased with stage and grade
whereas expression of p21 protein showed the opposite tendency
(Tables I and 2). Accordingly, when averaged across all tumour
stages, increased p21 expression did not correlate with either
the presence or the absence of p53 accumulation (Table 3). In
urothelial carcinoma accumulation of p53 protein, particularly
in advanced tumours, is usually due to mutations in the gene
(Cordon-Cardo et al, 1994; Williamson et al, 1994; Grimm et al,
1995; Uchida et al, 1995; Vet et al, 1995). This suggests that in the
majority of tumours staining positive for both proteins, p21 was
not induced by p53. Rather, the increase in p21 expression may
reflect a response to growth factors or inhibitors shown to be
capable of inducing p21 (Datto et al, 1995; Osawa et al, 1995;
Jakus and Yeudall, 1996). However, the situation in carcinoma in
situ and muscle-invasive tumours might be special. In carcinoma
in situ, all four lesions exhibiting p53 accumulation showed induc-
tion of p21. This could be due to induction of p21 in spite of
mutated p53 by alternate inducers, or the accumulated p53 could
represent activated wild-type protein inducing p21 expression in
these early stage tumours. Conversely, none of the muscle-
invasive tumours with p53 accumulation showed immunohisto-
chemically detectable p21 protein suggesting that at this stage
wild-type p53 protein might be required for p21 expression. In
accord with this finding, Malkowicz et al (1996) observed a good
correlation between diminished p2] mRNA expression and p53
mutations in advanced urothelial tumours.
Finally, the mRNA and protein expression data in urothelial
carcinoma and lung cancers parallelled each other, in accord with
data from model systems indicating that p21 expression is mainly
regulated at the level ofmRNA. Analysis of WAF] mRNA expres-
sion in urothelial carcinomas revealed widely divergent levels
between individual tumours (Table 5) in accord with the immuno-
histochemical data. Five tumours showed increased mRNA
expression above the range of normal mucosa. Notably, two ofthe
highest values were found in tumours (nos 35 and 41) with squa-
mous metaplasia, whereas in a single case ofadenocarcinoma (no.
36) the level of WAF] mRNA wasjust outside the range ofnormal
tissue. Although the identity is probably incidental, the fraction
of tumours showing higher expression of WAFI/p21 than
normal mucosa compares well with the five tumours positive in
immunohistochemistry and suggests that increased mRNA expres-
sion underlies protein over-expression as seen in lung tumours
(Marchetti et al, 1996). However, 6 of the 15 tumours, all high
grade and stage, had mRNA levels below the range of normal
mucosa. As the p21 protein level in normal mucosa is not suffi-
ciently high to yield positive staining, decreases in p21 expression
would obviously go undetected in immunohistochemical analysis.
Thus, whereas overexpression of p21 is frequently observed in
low-grade, early stage tumours, in many advanced, high-grade
tumours p21 expression may in fact be diminished. Again, our
data is in accord with the recent study of Malkowicz et al (1996)
showing diminished mRNA expression of WAFI/p21 in invasive
compared with superficial urothelial tumours. In addition,
although mutations in the WAFI/p21 gene are not very frequent
according to comprehensive investigations of a wide variety of
human tumours (Shiohara et al, 1994; Gao et al, 1995; Watanabe et
al, 1995) and none was found in our study, individual bladder
tumours may contain mutations in the coding region of WAFI/p21.
For instance, Malkowicz et al (1996) reported WAFJ mutations in
4 out of28 primary bladder cancers and that the bladder carcinoma
cell line HT1376 contains a frameshift mutation (Kawasaki et al,
1996). Furthermore, tumours showing very low expression such as
sample no. 3 in our study (Table 5) may contain genetic alterations
outside the coding region.
After its identification as a mediator of cell cycle arrest by p53
and presumably other factors, WAFI/p2] was considered a prime
candidate for being a tumour-suppressor gene. However, muta-
tions and deletions of the gene have turned out to be infrequent
(Shiohara et al, 1994; Gao et al, 1995; Watanabe et al, 1995;
Malkowicz et al, 1996). Moreover, expression of WAF1 protein
has been found in several types of human cancer. These results
may be related to the observation that whereas high expression of
p21 is associated with terminal differentiation moderate levels of
p21 expression can be found in proliferating cells (El-Deiry et al,
1995; McLeod et al, 1995). The function of p21 in proliferating
cells is not exactly known but may involve the coordination of
cyclin/cyclin-dependent kinase assembly (LaBaer et al, 1997).
Conceivably, expression of p21 in well-differentiated tumours
may reflect this situation even although in this species protein
levels sufficient to impede the cell cycle may sometimes be
reached. Most higher stage, low-grade tumours may possess lower
p21 levels permitting rather than inhibiting proliferation or even
lose p21 function because of down-regulation or mutation.
Concerning the clinical use of p21 as an inhibitor of cancer, this
interpretation would predict that advanced urothelial tumours may
be sensitive to growth inhibition by induction or transfer ofp21, if
and only if it is provided at a high level.
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